Pan-RAS Inhibitor Daraxonrasib Delivers Landmark Survival Gains in Pancreatic Cancer

Pancreatic ductal adenocarcinoma has long stood as one of medicine’s most formidable adversaries, a disease that claims the lives of the overwhelming majority of those it touches. More than 80 percent of patients are diagnosed only after the cancer has advanced beyond the reach of surgery, and the five-year survival rate has remained stubbornly fixed at approximately 13 percent. For patients whose disease has metastasized, first-line chemotherapy regimens deliver a median overall survival of less than one year, and the picture in the second-line setting is bleaker still: objective response rates usually fall below 10 percent, progression-free survival stretches to a mere two to three months, and median overall survival ranges from five to seven months. Over the past two decades, more than 20 second-line clinical trials have been launched, and nearly all have failed. That is precisely why the near-simultaneous publication of two studies of the drug daraxonrasib in the New England Journal of Medicine is being hailed as a historic turning point, a moment when a therapeutic stagnation that has persisted for generations may finally be breaking.

The story of this breakthrough begins with the RAS family of proteins, the quintessential molecular villains of pancreatic cancer. RAS mutations are present in more than 90 percent of pancreatic ductal adenocarcinoma cases, with the KRAS G12D, G12V, and G12R subtypes being the most frequent. For roughly four decades, these proteins were branded “undruggable.” The problem was structural: RAS proteins present a smooth, near-spherical surface lacking the classical deep pockets that small-molecule drugs typically exploit for binding. The arrival of KRAS G12C inhibitors cracked that impasse, proving that a chemical handle could be found on this notoriously slippery target. Yet the victory was narrow. G12C mutations account for only 1 to 2 percent of pancreatic cancers, limiting the clinical reach of those agents to a vanishingly small fraction of the patient population that desperately needs them.

Daraxonrasib, developed from the investigational compound RMC-6236, takes a fundamentally different pharmacological route. Rather than locking onto a single mutant allele in its inactive, GDP-bound state, the drug employs what its developers call RAS(ON) multi-selective inhibition. It is a non-covalent tri-complex inhibitor: the molecule first binds intracellular cyclophilin A to form a binary complex, and that complex then selectively attaches to the active, GTP-bound conformation of RAS proteins. Because it targets the switched-on state that drives cancer signaling, it can simultaneously cover a broad spectrum of RAS isoforms — KRAS, NRAS, and HRAS — and mutant alleles including G12D, G12V, G12R, G13, and Q61. This breadth transforms the calculus of RAS therapy. A strategy that once addressed a sliver of patients now reaches more than 90 percent of those with pancreatic cancer, marking a fundamental transition from allele-specific inhibition to broad-spectrum suppression of the RAS signaling engine.

The clinical evidence underpinning this shift has accumulated with unusual speed and rigor. In the phase I/II trial reported by Wolpin and colleagues, 168 patients with previously treated advanced RAS-mutant pancreatic cancer were enrolled. Among those with RAS G12 mutations receiving the 300-milligram dose as second-line therapy, the objective response rate reached 35 percent, the disease control rate was a striking 92 percent, and median duration of response, progression-free survival, and overall survival were 8.2, 8.5, and 13.1 months, respectively. Across all RAS-mutant patients carrying G12, G13, or Q61 alterations, the response rate was 29 percent with a median overall survival of 15.6 months. Grade 3 or higher treatment-related adverse events occurred in 30 percent of patients, predominantly rash and gastrointestinal toxicities, both of which proved manageable with standard clinical interventions.

Building on that foundation, O’Reilly and colleagues advanced daraxonrasib into the phase III RASolute 302 trial, an open-label randomized controlled study of 500 patients with previously treated metastatic pancreatic cancer, 91.8 percent of whom harbored RAS G12 mutations. The results were decisive. In the RAS G12 population, daraxonrasib achieved a median overall survival of 13.2 months compared with 6.6 months for chemotherapy, corresponding to a hazard ratio of 0.40 with a P value below 0.001. Median progression-free survival doubled from 3.5 to 7.3 months, again with a hazard ratio of 0.45. The intention-to-treat analysis yielded nearly identical figures — 13.2 versus 6.7 months — underscoring the robustness of the effect. Notably, the response rate in the daraxonrasib arm was 31.6 percent, roughly triple the 11.2 percent seen with chemotherapy. Patient-reported quality of life and time to pain deterioration, metrics that carry enormous weight in a disease defined by debilitation, were also significantly improved.

The safety profile added further weight to the case. Grade 3 or higher treatment-related adverse events occurred in 43.6 percent of patients receiving daraxonrasib, lower than the 57.5 percent observed with chemotherapy. Treatment discontinuation due to adverse events was just 1.2 percent with the targeted agent compared with 11.2 percent with chemotherapy. Rash and diarrhea were the most common side effects, but the majority were grade 1 to 2 and could be managed with routine clinical measures. For a drug that intervenes directly on what was long considered the most intractable target in oncology, this tolerability profile represents a remarkable pharmacological achievement.

Placed in historical context, the magnitude of these results becomes even more apparent. A median overall survival of 13.2 months, achieved in the second-line setting, surpasses the historic benchmark of FOLFIRINOX as a first-line regimen, which delivered 11.1 months. The 42-second standing ovation that greeted the data at the ASCO 2026 plenary session reflected not mere numerical progress but a genuine paradigm shift in treatment strategy. The implications extend to surgical oncology as well: approximately 39 percent of patients in the phase I/II study had previously undergone pancreatic resection, a population for whom effective second-line options have long been lacking. Daraxonrasib now offers these patients a meaningful alternative, and given its robust efficacy in advanced disease, investigators argue that moving the drug into the adjuvant or neoadjuvant setting deserves serious consideration.

Still, a measured perspective is warranted. Both published studies were industry-sponsored, and independent real-world validation remains essential before the results are universally adopted into practice. Although rash and gastrointestinal toxicities were predominantly low-grade, standardized management protocols will need to be established as clinical use expands beyond the controlled environment of a trial. Acquired resistance, an inevitability in targeted therapy, is expected to emerge through several mechanisms, including secondary KRAS mutations, bypass pathway activation through EGFR, HER2, or the PI3K–AKT–mTOR axis, adaptive upregulation of downstream effectors such as RAF or MEK, and tri-complex disruption via RAS Y64 or RAS Y71/BRAF alterations. Research to delineate these escape routes is already underway, and combination strategies — pairing daraxonrasib with chemotherapy, immunotherapy, or other targeted agents — will be critical to sustaining durable responses.

The broader RAS-targeted landscape is also evolving rapidly. Clinical trials of KRAS G12D-specific inhibitors, including VS-7375 and setidegrasib, are actively recruiting patients, and the strategic relationship between pan-RAS inhibitors covering multiple isoforms and mutants and allele-specific agents targeting a single variant — whether complementary or competitive — will be one of the defining questions of the coming years. What is no longer in dispute is the central lesson of this moment. RAS was long regarded as the holy grail of undruggable targets, a protein that defied every attempt at pharmacological conquest. Daraxonrasib has demonstrated that this target is not only tractable but capable of delivering tangible survival benefits and quality-of-life improvements to the patients who need them most. For the oncologists and surgeons who have long confronted the most recalcitrant of malignancies, the concurrent arrival of these two landmark studies marks the formal entry of pancreatic cancer therapeutics into the RAS-targeted era — a long-awaited dawn that has, at last, broken.

Subject of Research: Pan-RAS(ON) multi-selective inhibitor daraxonrasib as second-line therapy for RAS-mutated metastatic pancreatic ductal adenocarcinoma

Article Title: The dawn of RAS-targeted therapy: a landmark breakthrough of daraxonrasib in pancreatic cancer

Article References: Liu, C., & Liu, L. (2026). The dawn of RAS-targeted therapy: a landmark breakthrough of daraxonrasib in pancreatic cancer. Clinical Cancer Bulletin, 5(1), Article 20. https://doi.org/10.1007/s44272-026-00072-4

Image Credits: AI Generated

DOI: 10.1007/s44272-026-00072-4

Keywords: pancreatic cancer, daraxonrasib, RAS-targeted therapy, KRAS mutations, RASolute 302, targeted therapy, clinical trial, oncology, drug resistance, second-line treatment, molecular inhibition, precision medicine